Drug reference

Lomustine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 969, 970

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Lomustine is a lipid-soluble nitrosourea.

PDF page 969

Indications And Dose

Hodgkin’s disease resistant to conventional therapy | Malignant melanoma | Certain solid tumours ▶BY MOUTH ▶Adult: 120–130 mg/m2 every 6–8 weeks, dose is for when lomustine is used alone

PDF page 969

Contra Indications

Coeliac disease

PDF page 969

Prescribing And Dispensing Information

The brand name CCNU ® has been used for lomustine capsules.

PDF page 970

Safety

Important Safety Information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.

PDF page 969

Interactions

→Appendix 1: alkylating agents

PDF page 969

Side Effects

▶Common or very common Leucopenia ▶Frequency not known Alopecia. anaemia. apathy. appetite decreased. azotaemia. bone marrow failure (delayed). confusion. coordination abnormal. diarrhoea. hepatic disorders. lethargy. nausea. neoplasms. neurological effects. renal disorders. renal impairment. respiratory disorders. speech impairment. stomatitis. thrombocytopenia. vision loss (irreversible). vomiting SIDE-EFFECTS, FURTHER INFORMATION Prolonged use of lomustine is associated with an increased incidence of acute leukaemias.

PDF page 969

Conception And Contraception

Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 969

Pregnancy

Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 969

Breast Feeding

Discontinue breast-feeding.

PDF page 970

Renal Impairment

Avoid in severe impairment.

PDF page 970

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule Capsule ▶Lomustine (Non-proprietary) Lomustine 40 mg Lomustine 40mg capsules | 20 capsule P £780.82 ▶CeeNU (Imported (United States)) Immune system and malignant disease Lomustine 10 mg CeeNU 10mg capsules | 20 capsule P s Lomustine 100 mg CeeNU 100mg capsules | 20 capsule P s

PDF page 970

Dose text by age group

Adult

120–130 mg/m2 every 6–8 weeks, dose is for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 969

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Lomustine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 969, 970

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Lomustine is a lipid-soluble nitrosourea.

PDF page 969

Indications And Dose

Hodgkin’s disease resistant to conventional therapy | Malignant melanoma | Certain solid tumours ▶BY MOUTH ▶Adult: 120–130 mg/m2 every 6–8 weeks, dose is for when lomustine is used alone

PDF page 969

Contra Indications

Coeliac disease

PDF page 969

Prescribing And Dispensing Information

The brand name CCNU ® has been used for lomustine capsules.

PDF page 970

Safety

Important Safety Information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.

PDF page 969

Interactions

→Appendix 1: alkylating agents

PDF page 969

Side Effects

PDF page 969

Conception And Contraception

Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 969

Pregnancy

Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 969

Breast Feeding

Discontinue breast-feeding.

PDF page 970

Renal Impairment

Avoid in severe impairment.

PDF page 970

Dose and formulations

Medicinal Forms

PDF page 970

Dose text by age group

Adult

120–130 mg/m2 every 6–8 weeks, dose is for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 969

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.